Aclaris Therapeutics (ACRS) Payables: 2017-2025
Historic Payables for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $9.2 million.
- Aclaris Therapeutics' Payables rose 19.90% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year decrease of 16.15%. This contributed to the annual value of $4.7 million for FY2024, which is 47.17% down from last year.
- Per Aclaris Therapeutics' latest filing, its Payables stood at $9.2 million for Q3 2025, which was up 4.43% from $8.8 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Payables registered a high of $11.4 million during Q2 2023, and its lowest value of $4.2 million during Q2 2021.
- Moreover, its 3-year median value for Payables was $8.8 million (2025), whereas its average is $8.4 million.
- Its Payables has fluctuated over the past 5 years, first skyrocketed by 100.33% in 2023, then plummeted by 47.17% in 2024.
- Quarterly analysis of 5 years shows Aclaris Therapeutics' Payables stood at $10.0 million in 2021, then grew by 3.67% to $10.4 million in 2022, then declined by 14.23% to $8.9 million in 2023, then tumbled by 47.17% to $4.7 million in 2024, then increased by 19.90% to $9.2 million in 2025.
- Its Payables stands at $9.2 million for Q3 2025, versus $8.8 million for Q2 2025 and $6.4 million for Q1 2025.